603676 Tibet Weixinkang Pharmaceutical
- 9.06
- +0.09+1.00%
Tibet Weixinkang Pharmaceutical News
Express News | Wei Xinkang: Subsidiary Yangpu Jingtai obtained registration certificates for various micronutrient injections
Express News | Wei Xinkang: Liu Feng and others plan to reduce their holdings by no more than 0.33% in total
Wei Xinkang (603676.SH): Does not involve synthetic biotechnology
Gelonghui, May 9丨Wei Xinkang (603676.SH) said on the investor interactive platform that the company's main business is R&D, production, and sales of chemical preparations and their APIs, and is currently not involved in synthetic biotechnology.
Weixinkang (603676.SH) subsidiary obtained drug registration certificate for potassium aspartate injection
Zhitong Finance App News, Wei Xinkang (603676.SH) issued an announcement. Recently, Yangpu Jingtai Pharmaceutical Co., Ltd. (“Yangpu Jingtai”), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for potassium aspartate injections approved and issued by the State Drug Administration. Potassium aspartate injection is an electrolyte supplement. It is used for hypokalemia caused by various causes. This product can be used to supplement potassium when the following symptoms or conditions occur: when combined with antihypertensive diuretics, adrenocortical hormones, cardiac glycosides, insulin, or certain antibiotics; low-potassium periodic limb paralysis; hypokalemia in the case of heart disease
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
Wei Xinkang (603676.SH) announced first-quarter results, net profit of 94.914,700 yuan, an increase of 57.54% year-on-year
Wei Xinkang (603676.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 3...
Wei Xinkang (603676.SH): Received 41.8641 million yuan in government grants
Gelonghui, March 29丨Wei Xinkang (603676.SH) announced that Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received 418.64,100 yuan in government subsidies related to revenue, accounting for 23.66% of the company's 2022 audited net profit attributable to shareholders of listed companies.
[Instant Analysis of BT Financial Report] Wei Xinkang 2023 Third Quarter Report: Net profit increased significantly, balance ratio declined, and net operating cash flow decreased
Announcement time of this financial report: 2023-10-24 16:07:53 Wei Xinkang (stock code: 603676) is a comprehensive pharmaceutical enterprise, mainly engaged in pharmaceutical R&D, production and sales. According to earnings data for the third quarter of 2023, there are some notable changes in the company's operating conditions and financial performance. First, in terms of assets and liabilities, Wei Xinkang's total assets reached 1,772 billion yuan at the end of this reporting period, up from 1,665 billion yuan at the end of the previous year. Total liabilities at the end of this reporting period were $428 million, compared to 444 million yuan at the end of the previous year
Wei Xinkang (603676.SH): Net profit for the third quarter was 76.2395 million yuan, up 58.78% year on year
Glonghui, Oct. 24, 丨 Wei Xinkang (603676.SH) announced its report for the third quarter of 2023. Revenue for the reporting period was 312 million yuan, down 21.89% year on year; net profit attributable to shareholders of listed companies was 76.2395 million yuan, up 58.78% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 38.646 million, down 18.30% year on year; basic earnings per share were 0.18 yuan/share.
Wei Xinkang (603676.SH): Currently not involving drugs related to the prevention of Mycoplasma pneumoniae infection
Glonghui, Oct. 19, 丨 Wei Xinkang (603676.SH) said on the investor interactive platform that the company's main products cover vitamins, trace elements, electrolytes, etc. in parenteral nutritional drugs; there are currently no drugs related to preventing Mycoplasma pneumoniae infection.
Wei Xinkang (603676.SH) subsidiary obtained a multi-vitamin injection (13) (10/3) drug registration certificate
Wei Xinkang (603676.SH) issued an announcement. Recently, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Wei Xinkang (603676.SH): Newly approved potential pediatric compound amino acid injections and amino acids and trace elements under development will increase performance
GLONGHUI, September 28, Sept. 28 | Wei Xinkang (603676.SH) said that in recent years, promising pediatric amino acid injections (19AA-I), compound amino acid injections (20AA), acetylcysteine solutions for inhalation, compound electrolyte injections (II), compound electrolyte injections (II), compound electrolyte injections (V), mixed glycoelectrolyte injections, and the amino acids, trace elements, and parenteral nutritional drugs being developed by the company will all bring about an increase in performance after listing. From a long-term perspective, with the development of the concept of nutritional treatment, nutritional treatment will become a long track, and future development can be expected
Wei Xinkang (603676): Multi-dimensional (12) steady growth awaits the release of medical insurance for new products
Incident: The company recently released its 2023 semi-annual report. In the first half of 2023, it achieved revenue of 749 million yuan (yoy +12.18%); net profit of 134 million yuan (yoy +30.13%); deducted non-attributable income
Wei Xinkang (603676): R&D investment continues to increase and the product matrix continues to be enriched
Incident Wei Xinkang recently released its report for the first half of 2023: In the first half of 2023, the company achieved revenue of 750 million yuan (+12.2%), net profit of 130 million yuan (+30.1%), net profit attributable to parent, 130 million yuan (+30.1%), minus net profit not attributable to parent, 130 million yuan (+30.1%)
Wei Xinkang (603676): Performance growth was in line with market expectations, and profitability showed a month-on-month increase
Event Overview The company released its 2023 interim report: In the first half of '23, it achieved operating income of 749 million yuan, a year-on-year increase of 12.18%, net profit of 134 million yuan, a year-on-year increase of 30.13%, and achieved deduction
Wei Xinkang (603676.SH): Net profit for the first half of the year was 134 million yuan, up 30.13% year on year
Glonghui, August 22: Wei Xinkang (603676.SH) announced its 2023 semi-annual report. During the reporting period, it achieved operating income of 749 million yuan, an increase of 12.18%; net profit attributable to shareholders of listed companies was 134 million yuan, up 30.13% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 131 million yuan, an increase of 29.32% over the previous year; and basic earnings per share of 0.31 yuan.
Wei Xinkang (603676.SH): Service revenue mainly comes from cooperative products such as injectable multivitamin (12) and sucrose iron injections
On July 31, GLONGHUI|WEI Xinkang (603676.SH) recently said in response to a survey from institutional investors that service revenue is mainly patent and technology usage fees, trademark/brand usage fees, market management and promotion service fees charged to partners. After the implementation of the “two-ticket system”, since some products produced cooperatively could not be sold by the company, the cooperative manufacturer sold and shipped the cooperative products produced to designated pharmaceutical distribution enterprises according to the company's orders. The company dominated the entire market management and promotion service business. The company charged technology usage fees, trademark usage fees, market management and promotion from the cooperative manufacturers
Wei Xinkang (603676.SH): Most of the company's products are exclusive domestic products or exclusive domestic varieties, which do not meet the requirements for national procurement
On July 31, GLONGHUI|WEI Xinkang (603676.SH) recently said in response to a survey from institutional investors that according to the latest national collection rules, 1 original research company and 3 generic drugs that have passed the consistency evaluation meet the national collection conditions. Most of the company's products are exclusive domestic products or exclusive domestic varieties, which do not meet the conditions for national procurement yet. Some provinces have issued collection policy documents. The company is actively responding, seeking more market opportunities and achieving sustainable and stable development.
Wei Xinkang (603676.SH): The Market Management Center has three organizational modules: sales team, functional departments, and compliance system
In response to a recent survey from institutional investors, GLONGHUI (603676.SH) stated that the company's market management center has three organizational modules: sales team, functional department, and compliance system. Among them, the sales team has a division system as the core and is divided into the first division, platform division, and new product division according to the products and components they are responsible for.
Wei Xinkang (603676): New parenteral nutrition product cycle kicks off
Key investment points The company is a leading enterprise focusing on parenteral nutrition during perioperative parenteral nutrition. The product competition pattern is good, and the continuous expansion of pipelines has led to continuous rapid growth in performance. We believe that since 2021, with the company's core product, injectable 12 doses
Analysis
Price Target
No Data
